Skip to main content

Advertisement

SpringerLink
Log in

Oral nystatin as antifungal prophylaxis in critically ill patients: an old SDD tool to be renewed?

  • Editorial
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP (1988) Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 148:2642–2645

    Article  PubMed  Google Scholar 

  2. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sablen C, Kartsonis N, Perfect J for the Caspofungin Invasive Candidiasis Study Group (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020–2029

    Article  PubMed  Google Scholar 

  3. Prella M, Bille J, Pugnale M, Duvoisin B, Cavassini M, Calandra T, Marchetti O (2005) Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagn Microbiol Infect Dis 51:95–101

    Article  PubMed  Google Scholar 

  4. Eggimann P, Garbino J, Pittet D (2003) Epidemiology of Candida species infections in critically-ill non-immunosuppressed patients. Lancet Infect Dis 3:685–702

    Article  PubMed  Google Scholar 

  5. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP (1989) Risk factors for hospital-acquired candidemia. Arch Intern Med 149:2349–2353

    Article  PubMed  Google Scholar 

  6. Calandra T, Bille J, Schneider R, Mosimann F, Francioli P (1989) Clinical significance of Candida isolated from peritoneum in surgical patients Lancet II:1437–440

    Google Scholar 

  7. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP, National Epidemiology of Mycoses Survey (NEMIS) Study Group (2001) Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 33:177–186

    Article  PubMed  Google Scholar 

  8. Bow EJ, Laverdiere M, Lussier N, Totstein C, Cheang MS, Ioannou S (2002) Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 94:3230–3246

    Article  PubMed  Google Scholar 

  9. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE (2004) Guidelines for treatment of candidiasis Clin Infect Dis 38:161–189

    Article  Google Scholar 

  10. Anaissie EJ, Rex JH, Uzun O, Vartivarian S (1998) Predictors of adverse outcome in cancer patients with candidemia. Am J Med 104:238–245

    Article  PubMed  Google Scholar 

  11. Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Vandercam B, Doyen C, Lebeau B, Spence D, Krcmery V, De Pauw B, Meunier F (1999) Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 28:1071–1079

    PubMed  Google Scholar 

  12. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA,Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751

    Article  PubMed  Google Scholar 

  13. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ, SENTRY participant groups (2002) Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 40:852–856

    Article  PubMed  Google Scholar 

  14. Garbino J, Lew PD, Romand JA, Hugonnet S, Auckenthaler R, Pittet D (2002) Prevention of severe Candida infections in non-neutropenic, high-risk, critically ill patients. A randomized, double-blind, placebo-controlled trial in SDD-treated patients. Intensive Care Med 28:1708–1717

    Article  PubMed  Google Scholar 

  15. Dupont H, Bourichon A, Paugam-Burtz C, Mantz J, Desmonts JM (2003) Can yeast isolation in peritoneal fluid be predicted in intensive care unit patients with peritonitis? Crit Care Med 31:752–757

    Article  PubMed  Google Scholar 

  16. Piarroux R, Grenouillet F, Balvay P, Tran V, Blasco G, Milloin L, Boillot A (2004) Assessment of preemptive treatment to prevent severe candidiasis in critically-ill surgical patients. Crit Care Med 32:2443–2449

    Article  PubMed  Google Scholar 

  17. Eggimann P, Francioli P, Bille J, Schneider R, WU MM, Chapuis G, Chiolero R, Pannatier A, Schilling J, Geroulanos S, Glauser MP, Calandra T (1999) Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med 27:1066–1072

    Article  PubMed  Google Scholar 

  18. Cruciani M, de Lalla F, Mengoli C (2005) Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis. Intensive Care Med ( 10.1007/s00134-005-2794-y)

    Google Scholar 

  19. Normand S, François B, Dardé ML, Bouteille B, Bonnivard M, Preux PM, Gastinne H, Vignon P (2005) Oral nystatin prophylaxis of Candida spp. Colonization in ventilated critically-ill patients. Intensive Care Med (DOI: 10.1007/s00134-005-2807-x)

  20. Gotzsche PC, Johansen HK (2002). Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database Syst Rev

  21. Silvestri L, van Saene HK, Milanese M, Gregori D (2005) Impact of selective decontamination of the digestive tract on fungal carriage and infection: systematic review of randomized controlled trials. Intensive Care Med 31:898–910

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service des Soins Intensifs de Chirurgie et Centre des Brûlés, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

    Philippe Eggimann

  2. Service de Réanimation Médicale et des Maladies infectieuses, Hôpital Bichat-Claude Bernard, AP/HP, Paris, France

    Michel Wolff

  3. Service des Maladies Infectieuses, Département de Médecine Interne, Hôpitaux Universitaires de Genève, Geneva (HUG), Switzerland

    Jorge Garbino

Authors
  1. Philippe Eggimann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michel Wolff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jorge Garbino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philippe Eggimann.

Additional information

This editorial refers to the article available at: http://dx.doi.org/10.1007/s00134-005-2807-x

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eggimann, P., Wolff, M. & Garbino, J. Oral nystatin as antifungal prophylaxis in critically ill patients: an old SDD tool to be renewed?. Intensive Care Med 31, 1466–1468 (2005). https://doi.org/10.1007/s00134-005-2806-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-005-2806-y

Search

Navigation